Genmab is : A biotechnological company developing human antibodies for products used to treat life-threatening diseases, such as cancer, and disabling diseases such as the chronic inflammation. A biotechnology company creating and developing fully human antibodies for the treatment of life threatening and debilitating diseases. A biotechnology company formed by a group of danish investors, including bankinvest biomedical development fund, a/s dansk erhvervsinvestering, lonmodtagernes dyrtidsfond and leif helth care. A biotechnology company founded in 1999. A biotechnology company that creates and develops human abs for the treatment of life-threatening and debilitating diseases. A biotechnology company using transgenic mouse technology to create and develop human antibodies to treat a wide variety of life threatening and debilitating diseases. A product development company focused on creating a broad portfolio of human antibody products to treat a variety of diseases. A scandinavian based (denmark) company, developing fully human antibodies for therapeutic use. An international biotechnology company developing human antibody products for patients who are suffering from life-threatening and debilitating diseases. An international company. A biotech company developing human antibody therapies and treatments for cancer, rheumatoid arthritis and other diseases. Europe’s fifth largest biotech company and presently ranks among the world’s top 50 biotech companies by market capitalisation. Now a public limited company. The first danish biotechnology company dedicated exclusively to developing antibody products. The largest biotechnology company in utrecht that creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. Headquartered in copenhagen, denmark, and has operations in utrecht, the netherlands. Headquartered in copenhagen, denmark with locations in utrecht. In the process of generating human lead antibodies against this target. Well known for its excellence in developing antibody based therapies,” said rainer. Headquartered in denmark and has operations in utrecht, the netherlands and princeton, new. Headquartered in copenhagen, denmark and has operations in utrecht. Committed to a high standard of financial reporting. Publicly traded on the copenhagen stock exchange and the neuer markt of the frankfurt stock. Maintaining its financial guidance for the year. Founded as an independent company in copenhagen in february 1999. Founded as an independent company in copenhagen in march 1999, by medarex and a group of unrelated third party investors. Founded in year 1999. Founded in 1999 and has built an impressive clinical team as well as established broad. Reduced to its current level of approximately 33%. Founded in february 1999 and is publicly traded on the copenhagen stock exchange. Attracted to roche's manufacturing expertise and molecular targets, says drakeman. Access to the bigger company’s pre-clinical development and manufacturing capabilities and has been granted the right to use the patented humab-mouse technology. Reached two milestones in its collaboration with the swiss pharmaceutical company roche. Released promising drug trials on cancer drug humax-cd4 : danish biotech genmab a/s. Four products in development to treat. Been exemplary," said lisa n. Four products in development, including one in human clinical trials. Products in development to treat cancer, infectious disease, rheumatoid arthritis and other inflammatory conditions. Been nominated for the 2005 world technology award for biotechnology. Numerous products in development, from pre. Numerous products in development to treat cancer, infectious disease, rheumatoid arthritis and other inflammatory. Been granted fast track status for its agent humax - egfr by the us food and drug. Just announced a new clinical trial of their fully humanized monoclonal antibody. The development of therapeutic antibodies. De første tre kvartaler i 2002 peger på et driftstab på mindst 450 mio. The il-15 antibody programme. The use of the humab mouse to generate human antibodies. Expansion in collaboration. Therapeutic antibody development. More important than for drugs. A complex and still controver-guweb. Producing phbv poly- mers. Human use being developed for marketing, and electronic products. Implementing biological control programs. The design, construction and qualification of a new production unit for japanese. Unrestricted shipment in or from the united states under the vsta, as amended. The american market 17. The life sciences market. |
